ProteinQure’s Post

Plus Therapeutics presented data on its novel radioisotope rhenium-186 at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in Toronto. Link to presentation: https://bit.ly/4bd9GyB An oral presentation titled, “Radiation Absorbed Dose to Spinal Cord: Therapy of Leptomeningeal Metastases Using Beta-Emission Pharmaceuticals”, brief highlights: - Data from the ReSPECT-LM clinical trial was used to evaluate the safety and potential spinal cord toxicity of beta-emission radioisotopes, including 177Lu, 131I, 186Re, 188Re, and 90Y - Higher beta-energy emitters (i.e., 188Re and 90Y) give higher radiation absorbed doses to spinal cord with more heterogeneous radiation absorbed doses to spinal fluid - Lower beta-energy radionuclides (177Lu, 131I, and 186Re) can largely spare the spinal cord, presenting a promising approach to minimize toxicity while delivering high doses to eradicate cancer cells #nuclearmedicine #clinicaltrials #radiotherapy

Bromo Biliaron is a radiopharmaceutical used in hepatobiliary imaging, and it contains bromotrimethylaminomethyliminodiacetic acid (mebrofenin) labeled with the radioisotope technetium-99m (Tc-99m). Tc-99m Mebrofenin (technetium-99m mebrofenin) is a radiopharmaceutical used in nuclear medicine, primarily for hepatobiliary imaging. It helps in evaluating liver function, gallbladder function, and the patency of the bile ducts. Technetium-99m (Tc-99m) is a widely used radioisotope in diagnostic imaging because of its ideal physical characteristics, including a half-life of approximately 6 hours and the emission of gamma rays suitable for detection with a gamma camera. 🖇️ Mechanism of Action After intravenous injection, mebrofenin is taken up by hepatocytes and excreted into the bile. The Tc-99m emits gamma rays, which can be detected by a gamma camera to produce images of the hepatobiliary system. Photo by: Dame Ria Silaban #nuclearmedicine

PanTera was set up in September 2022 as a joint venture between Belgium’s nuclear research centre SCK CEN and IBN (Ion Beam Applications) with the mission to commercialise the production of Ac-225 from radium-226 (Ra-226) with the use of accelerator technology. Ac-225 is a promising alpha emitter for use in targeted alpha therapy. It has the potential to target solid tumors, metastases, and systemic cancers such as leukemia. The company’s production method transforms Ra-226 into Ra-225, which then decays into Ac-225. This process will enable PanTera to produce over 100 Curies of clinical-grade Ac-225. annually by 2029, enough to treat more than 100,000 cancer patients each year.  #Nuclear #AdvancedNuclear #SGEC  https://lnkd.in/eyYG43aT

🇳🇱⚛️🤝 NRGIPALLAS (ENS Corporate Member) and Curium Pharma have signed a long-term agreement to expand the current #cooperation to include the production of #lutetium-177 (Lu-177). This agreement will enable Curium to supply about 70,000 doses of Lu-177 annually, which will help about 14,000 patients per year. 🏥⚛️❤️ Lu-177 is currently used in hospitals to treat neuroendocrine tumours, and it is also a very promising #radioisotope used in the fight against prostate cancer and dozens of other applications soon. That's why the need for Lu-177 is expected to grow exponentially: from 16,000 patients in 2020 to 138,000 patients in 2026. 🔬⚛️🚚 NRGIPALLAS’ HFR reactor and Curium’s Lu-177 production facility are both located at the Energy & Health Campus in #Petten, which also means that no time is lost in the production of lutetium (half-life) and the #nuclear #medicine can reach #patients as quickly as possible. ✅ https://lnkd.in/dQNJ_V69

In support of World Cancer Day on 4th February, our employees from around the world enjoyed a webinar featuring insights into cancer from a world-renowned Medical Oncologist from Stanford University, as well as Curium’s CEO International Markets & Chief M&A Officer Chaitanya Tatineni, who highlighted Curium's pivotal role in reshaping the future of cancer diagnosis and therapy.   Curium thrives on pushing boundaries, turning challenges into opportunities, and making the impossible possible for patients and their families. Find out more about how we are redefining the experience of cancer through our trusted legacy in nuclear medicine here: https://lnkd.in/dSpf-ENs   #WorldCancerDay #WCD2024 #NETs #radiopharmaceuticals #nuclearmedicine #clinicaltrials #ProstateCancer #NeuroendocrineTumors #PET #SPECT #MolecularImaging #NucMed #LegacyOfExcellence #TrustedInnovation #Curium #CancerWebinar #MakingADifference #EverydayImpact

RENAL CELL CARCINOMA can be hard to see with 18F-FDG and more if the reader Is improvised or inexperienced. In clinical practice we are expecting have new radiotracers like the one that Telix Pharmaceuticals Limited is in ways of development. | The MedicinaNuclearMX collective are Mexican Nuclear Medicine Physicians promoting, expanding clinical use & doing disruptive business by private sector in Mexico. #molecularimaging #nuclearmedicine #theranostics #radionuclidetherapy #renalcancer

Enabling healthcare potential starts from looking for the Future of Nuclear Medicine in Oncology! Glad to supports the experts! on March 8, in Rome at Fondazione Policlinico Universitario Agostino Gemelli IRCCS #thyroidcancer #NEN #prostatecancer #research #nuclearmedicine #medicinanucleare #theranostics #radiopharmaceuticals #innovationinhealthcare #oncology Ergéa

The data, published in the International Journal of Molecular Sciences, demonstrate that opaganib significantly improved long-term survival in an in vivo model of lung damage following exposure to ionizing radiation Opaganib is the first selective sphingosine kinase-2 (SPHK2) inhibitor investigational drug targeting sphingolipid metabolism for the treatment of radiation-induced inflammation Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute, supporting potential central government stockpiling for use as radioprotection therapy in mass casualty radiological or nuclear incidents, if approved by the FDA https://lnkd.in/gUrmXe9A

🌟 Introducing IsoMedica (an entX Limited company)! 🌟 We’re excited to unveil our new brand dedicated to Nuclear Medicine supply chains, IsoMedica. At IsoMedica, we're pioneering Mine to Medicine technologies to recover valuable isotopes from low-level radioactive waste streams as well as providing valuable precursors to the nuclear medicine supply chain. These isotopes will feed critical and emerging cancer therapy treatments. Our mission extends beyond innovation – we're reshaping the landscape of cancer therapy by breaking reliance on existing supply chains. With geopolitical issues causing instability in some countries, creating a sovereign supply chain is essential. By doing so, we're enhancing the availability and reducing the cost of future cancer treatments, not just in Australia, but across the globe. Join us in this groundbreaking journey towards a brighter, more accessible future for cancer care. Read more: 👉 https://lnkd.in/gKc2J6tF #IsoMedica #CancerTherapy #Innovation #entX #Radiopharmaceuticals #NuclearMedicine #IsotopeRecovery #MedTech #GlobalHealthcare #CancerResearch #SupplyChainSecurity #AccessibleTreatment #FutureOfMedicine #Australia #minestomedicines Massey de los Reyes | Julian F. Kelly | Bryn Jones

Cancer treatment: Actinium -225 Actinium-225 is used in nuclear medicine for malignant tumors treatment. It can be applied to produce Bi-213 in a reusable generator or can be used alone as an agent for radiation therapy, in particular for targeted alpha therapy (TAT). Not only Ac-225 itself but also its decay products emit alpha particles which kill cancer cells in the body.